A previous report found that TAGLN was specifically expressed in 154 of 184 leiomyosarcoma (LMS) (84%) and could be used as a novel diagnosis marker for tumor of smooth muscle differentiation, especially for LMS [23]. This evidence concerns the gene TAGLN and leiomyosarcoma.